Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $10.92 and last traded at $11.32, with a volume of 341203 shares changing hands. The stock had previously closed at $11.98.
Maze Therapeutics Stock Down 5.5 %
About Maze Therapeutics
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
- Five stocks we like better than Maze Therapeutics
- How to Use the MarketBeat Stock Screener
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Want to Profit on the Downtrend? Downtrends, Explained.
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Profit From Growth Investing
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
